Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 163-171

  Kennedy, Mary Jayne ^a   Scripture, Charity D ^b   Kashuba, Angela D M ^b   Scott, Christy S ^b   Gaedigk, Andrea ^b   Kearns, Gregory L ^b  

^a University of Louisville School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; ISOENZYME; LIVER ENZYME; XANTHINE OXIDASE;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; EVALUATION; FEMALE; GENOTYPE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; STANDARD; URINALYSIS; VALIDATION PROCESS;

ARYLAMINE N-ACETYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CYSTIC FIBROSIS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; XANTHINE OXIDASE;

EID: 1542316308     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.10.005     Document Type: Article

References (52)

1. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr. 122:1993;1-9.
2. Bigger B., Coutelle C. Perspectives on gene therapy for cystic fibrosis airway disease. BioDrugs. 15:2001;615-634.
3. Isles A.F., Spino M., Tabachnik E., Levison H., Theissen J.J., MacLeod S.M. Theophylline disposition in cystic fibrosis. Am Rev Respir Dis. 127:1983;417-421.
4. Konstan M.W., Hoppel C.L., Chai B., Davis P.B. Ibuprofen in children with cystic fibrosis pharmacokinetics and adverse effects. J Pediatr. 118:1991;956-964.
5. Dove A.M., Szefler S.J., Hill M.R., Jusko W.J., Larsen G.L., Accurso F.J. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr. 120:1992;789-794.
6. Tan K.K.C., Hue K.L., Strickland S.E., Trull A.K., Smyth R.L., Scott J.P., et al. Altered pharmacokinetics of cyclosporine in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit. 12:1990;520-524.
7. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-24
8. Abramowsky C.R., Swinehart G.L. The nephropathy of cystic fibrosis a human model of chronic nephrotoxicity. Hum Pathol. 13:1982;934-939.
9. Goodchild M.C., Banks A.J., Drole Z., Anderson C.M. Liver scans in cystic fibrosis. Arch Dis Child. 50:1975;813-815.
10. Gaskin K.J., Waters S.L., Howman-Giles R., de Silva M., Earl J.W., Martin H.C., et al. Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med. 318:1988;340-346.
11. Kattwinkl J., Taussig L.M., Statland B.E., Vertes J.E. The effect of age on alkaline phosphatase and other serologic liver function tests in normal subjects and patients with cystic fibrosis. J Pediatr. 82:1973;234-242.
12. Kearns G.L., Crom W.R., Karlson K.H., Mallory G.B., Evans W.E. Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmacol Ther. 59:1996;529-540.
13. Knoppert D.C., Spino M., Beck R., Thiessen J.J., MacLeod S.M. Cystic fibrosis enhanced theophylline metabolism may be linked to the disease. Clin Pharmacol Ther. 44:1988;254-264.
14. Mimeault J., Vallee F., Seelman R., Sorgel F., Ruel M., LeBel M. Altered disposition of fleroxacin in patients with cystic fibrosis. Clin Pharmacol Ther. 47:1990;618-628.
15. Hutabarat R.M., Unadkat J.D., Sahajwalla C., McNamara S., Ramsey B., Smith A.L. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. Clin Pharmacol Ther. 49:1991;402-409.
16. Hutabarat R.M., Unadkat J.D., Kushmerick P., Aitken M.L., Slattery J.T., Smith A.L. Disposition of drugs in cystic fibrosis. III. Acetaminophen. Clin Pharmacol Ther. 50:1991;695-701.
17. Dranitsaris G., Spino M., Tesoro A., Phillips M.J., Cox K. Theophylline (THEO) biotransformation in normal and diseased human livers. [abstract] Clin Pharmacol Ther. 51:1992;162.
18. Hutabarat R.M., Smith A.L., Unadkat J.D. Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. Clin Pharmacol Ther. 55:1994;427-433.
19. O'Sullivan T.A., Wang J.P., Unadkat J.D., Al-Habet S.M.H., Trager W.F., Smith A.L., et al. Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin Pharmacol Ther. 54:1993;323-338.
20. Wang J.P., Unadakat J.D., McNamara S., O'Sullivan T.A., Smith A.L., Trager W.F., et al. Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including CYP3A4) is not enhanced in cystic fibrosis. Clin Pharmacol Ther. 55:1994;528-534.
21. Gremse D.A., Sindel L.J., Hoff C.J., Wells D.J., Boerth R.C. Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. J Pediatr Gastroenterol Nutr. 32:2001;434-437.
22. Bosso J.A., Liu Q., Evans W.E., Relling M.V. CYP2D5, N-acetylation and xanthine oxidase activity in cystic fibrosis. Pharmacotherapy. 16:1996;749-753.
23. Hamelin B.A., Xu K., Valle F., Manseau L., Richer M., LeBel M. Caffeine metabolism in cystic fibrosis enhanced xanthine oxidase activity. Clin Pharmacol Ther. 56:1994;521-529.
24. Parker A.C., Pritchard P., Preston T., Smyth R.L., Choonara I. Enhanced drug metabolism in young children with cystic fibrosis. Arch Dis Child. 77:1997;239-241.
25. Leeder J.S., Adcock K., Gaedigk A., Gotschall R., Wilson J.T., Kearns G.L. Acquisition of CYP2D6 and CYP3A4 activities in the first year of life. [abstract] Clin Pharmacol Ther. 67:2000;169.
26. Evans W.E., Relling M.V., Petros W.P., Meyer W.H., Mirro J., Crom W.R. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther. 45:1989;568-573.
27. Michalets E.L. Update clinically significant cytochrome P450 drug interactions. Pharmacotherapy. 18:1998;84-112.
28. Gaedigk A., Gotschall R.R., Forbes N.S., Simon S.D., Kearns G.L., Leeder J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 9:1999;669-682.
29. Gaedigk A., Bradford L.D., Marcucci K.A., Leeder J.S. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 72:2002;76-89.
30. Grant D., Tang B., Kalow W. A simple test for acetylator phenotyping using caffeine. Br J Clin Pharmacol. 17:1984;459-464.
31. Abdel-Rahman S.M., Gotschall R.R., Kauffman R.E., Leeder J.S.L., Kearns G.L. In vivo evaluation of terbinafine as a CYP2D6 inhibitor. Clin Pharmacol Ther. 65:1999;465-472.
32. Kashuba A.D.M., Bertino J.S., Kearns G.L., Leeder J.S.L., James A.W., Gotschall R.R., et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2 and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther. 63:1998;540-551.
33. Campbell M.E., Spielberg S.P., Kalow W. A urinary caffeine metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther. 42:1987;157-165.
34. Grant D.M., Tang B.K., Campbell M.E., Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol. 17:1984;459-464.
35. Tang B.K., Kadar D., Qian L., Iriah J., Yip J., Kalow W. Caffeine as a metabolic probe validation of its use for acetylator phenotyping. Clin Pharmacol Ther. 49:1991;648-657.
36. Schmid B., Bircher J., Preisig R., Kupfer A. Polymorphic dextromethorphan metabolism co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 38:1985;618-624.
37. Kashuba A.D.M., Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R.R., Rocco M.L., et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6 and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 64:1998;257-268.
38. Takemoto C.K., Hodding J.H., Kraus D.M. Pediatric dosage handbook. 7th ed :2000;LexiComp, Hudson (OH).
39. Cumming J.F. The effect of arterial oxygen tension on antipyrine half-life in plasma. Clin Pharmacol Ther. 19:1976;468-471.
40. Agnihotri S., Clark R., Cooper S. Chronic pulmonary disease and antipyrine disposition. Br J Clin Pharmacol. 5:1978;275-277.
41. Sonne J. Drug metabolism in liver disease implications for therapeutic monitoring. Ther Drug Monit. 18:1996;397-401.
42. Kearns G.L., Mallory G.B., Crom W.R., Evans W.E. Enhanced hepatic drug clearance in patients with cystic fibrosis. J Pediatr. 117:1990;972-979.
43. 13CO breath test. Pediatr Res. 23:1988;632-636.
44. Kalow W., Tang B.K. The use of caffeine for enzyme assays a critical appraisal. Clin Pharmacol Ther. 53:1993;503-514.
45. Philpot R.M., Smith B.R. Role of cytochrome P450 and related enzymes in the pulmonary metabolism of xenobiotics. Environ Health Perspect. 55:1981;359-367.
46. Gotschall R., Leeder J.S., Farrar H., McCubbin M., Johnson K., Kearns G.L. Caffeine plasma clearance in cystic fibrosis (CF) does not correlate with CYP1A2 activity. [abstract] Clin Pharmacol Ther. 63:1998;192.
47. Bianchetti M.G., Kraemer R., Passweg J., Jost J., Preisig R. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 5:1988;688-693.
48. Fuhr U., Rost K.L., Englehardt R., Sachs M., Liermann D., Belloc C., et al. Evaluation of caffeine as a test drug for CYP1A2, NAT-2 and CYP2E1 phenotyping in man by in-vivo versus in-vitro correlations. Pharmacogenetics. 6:1996;159-176.
49. Huang L., Vore M. Multidrug resistance p-glycoprotein 2 is essential for the biliary excretion of indocyanine green. Drug Metab Dispos. 29:2001;634-637.
50. Trezise A.E.O., Ratcliff R., Hawkins T.E., Evans M.J., Freeman T.C., Romano P.R., et al. Co-ordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice. Hum Mol Genet. 6:1997;527-537.
51. Trezie A.E.O., Romano P.R., Gill D.R., Hyde S.C., Sepulveda F.V., Buchwald M., et al. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J. 11:1992;4291-4303.
52. Kulkarni S.G., Pegram A.A., Smith P.C. Disposition of acetaminophen and indocyanine green in cystic fibrosis knockout mice. AAPS PharmSci. 2:2002;E18.